Redeye retains its positive view of Sdiptech following a Q4 report that exceeded our expectations.
Redeye raises its Fair Value range for Hexatronic following a solid Q4 report where EBITA beat our f...
Redeye comments on Alligator’s Q4 report. The key event during the quarter was mitazalimab showing s...
Redeye has postponed the expected release of the free-to-play game codenamed Vanguard in its researc...
Russian divestment leaves ~SEK 800m net cash On 23 December 2022, Ferronrodic announced the divestme...
A report in line with expectations Briox's Q4 had high growth and stable opex.
Redeye lowers its near-term profitability outlook for QleanAir following its profit warning.
Redeye retains its positive view of Proact following a strong Q4 report fueled by System sales.
Q4 sales of SEK 696m were 8% above ABGSCe With its strong order backlog and recent production data f...
North America focus in Q4 When BTS reported its Q3 the organic growth in its biggest segment, North ...
Stark avslutning på 2022 med ökade hyresintäkter och en föreslagen utdelningshöjning på 13%.
Sleep Cycle published its preliminary Q4 2022 numbers on January 16, in light of the back-then ongoi...
Kraftigt påverkat av komponentbristen Det fjärde kvartalet påverkas kraftigt av den tidigare meddela...
Stor projektportfölj med bred geografisk exponering, en hög ESG profil och attraktiv värdering Eolus...
Redeye states that Catella posted another solid quarter despite rather challenging market conditions...
Redeye believes that Sdiptech’s Q4 report was slightly better than our expectations.
Redeye updates its view on M.O.B.A. ahead of its Q4 2022 report due on February 15.
Takeaways from the Q4 report We were surprised by the pace with which the order bookings and the sal...
IAR Systems’ Q4 report was a slight hiccup in its accelerated profitable growth turnaround, but we s...
Remedy reported a Q4 with revenue of EUR 13.6 million exactly in line with our estimates and an EBIT...
